Genevax DNA-based genetic vaccine: Began a Phase I/II trial in Switzerland

The vaccine contains genes from the HIV envelope that support the synthesis of two HIV proteins in the cells of those vaccinated. The vaccine is designed to provoke an antigen response and generate cytotoxic T lymphocytes in patients. ...